Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis

Agashivala N, Kim E

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
22749258

DOI
10.1016/j.clinthera.2012.06.012

Original Paper URL

Indexing Status
Subject indexing assigned by NLM

MeSH
Adjuvants, Immunologic /economics /therapeutic use; Adolescent; Adult; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Double-Blind Method; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents /administration & dosage /economics /therapeutic use; Injections, Intramuscular; Interferon beta-1a; Interferon-beta /economics /therapeutic use; Middle Aged; Multiple Sclerosis, Relapsing-Remitting /drug therapy /economics; Propylene Glycols /administration & dosage /economics /therapeutic use; Sphingosine /administration & dosage /analogs & derivatives /economics /therapeutic use; Time Factors; Treatment Outcome; Young Adult

AccessionNumber
22012029151

Date bibliographic record published
30/01/2013